Seven Fleet Capital Management’s Summit Therapeutics SMMT Stock Holding History

Seven Fleet Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Buy	+73,300	New	+$1.3M	0.18%	58

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Seven Fleet Capital Management's SMMT Position: Q2 2026 in Review

Seven Fleet Capital Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 73,300 shares worth $1.09M. The stake represents 0.18% of the portfolio and ranks #58 among its holdings.

242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Seven Fleet Capital Management held 73,300 shares of Summit Therapeutics worth $1.09M as of Q2 2026.
Summit Therapeutics was a new Seven Fleet Capital Management position in Q2 2026.
Summit Therapeutics made up 0.18% of Seven Fleet Capital Management's portfolio in Q2 2026, its #58 holding.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.